QualityStocksNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering
Ocugen (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene and cell therapies and vaccines, has closed on its previously announced underwritten public offering. The offering was comprised of 30,434,783 shares of its common stock, with each share sold at $1.15 per share. The company is anticipated to receive an estimated $35 million in gross proceeds, before standard deductions and expenses are made. Ocugen plans to use the funds from the offering for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Titan Partners Group, a division of American Capital Partners, acted as…
